ComparaTOX™-1: In Vitro Comparative Toxicity Contract Services
We are in the process of updating this page
What is ComparaTOX™?
ComparaTOX™ is a unique, high throughput in vitro cytotoxicity screening platform that directly compares the response of cell types from different organs, tissues and species to drugs and other compounds using a single ATP bioluminescence readout technology that can be multiplexed with accessory assays to provide valuable correlative data to predict potential toxicity.
Advantages of using ComparaTOX™-1 to Predict and Rank Toxicity of Drugs and other Agents
- ComparTOX™ is used to detect potential toxicity in an array of different cell types derived from most cell systems and up to five different species.
- The assay platform uses the most sensitive ATP bioluminescence readout technology to measure potential cytotoxicity.
- ComparaTOX™-1 is built on Bioluminomics™ Technology that incorporates assay calibration and standardization to directly compare the response of different cell types using a single readout.
- ComparaTOX™-1 allows the ranking and direct comparison of IC and Area Under the Curve (AUC) values.
- Incorporates high throughput capability (Z Factor > 0.7) using either 96- or 384-well plates formats.
- The assay platform is designed specifically for proliferating or high metabolic rate cells.
- Both adherent and non-adherent cell types can be used.
- Each cell type is cultured in its own specific growth medium.
- Applicable to 3D in vitro cultures.
- A 3Rs Assay Platform: Helps Reductioin, Refinement, and Replacement for animal testing.
- Validated assay readout according to FDA Bioanalytical Method Guidelines.
- Available as GLP or non-GLP contract services.
- Fast turnaround time: Usually within 7 days or less depending on cell type and species.
For more information on ComparTOX™ Contract Services, please download the ComparaTOX™ Information Flyer or contact HemoGenix® to discuss how ComparaTOX™ can be used to achieve the goals of comparative toxicology.